Guizhou Yibai Pharmaceutical Co Ltd (SHG:600594) — Market Cap & Net Worth
Market Cap & Net Worth: Guizhou Yibai Pharmaceutical Co Ltd (600594)
Guizhou Yibai Pharmaceutical Co Ltd (SHG:600594) has a market capitalization of $385.89 Million (CN¥2.64 Billion) as of July 22, 2026. Listed on the SHG stock exchange, this China-based company holds position #13363 globally and #3835 in its home market, demonstrating a 0.30% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guizhou Yibai Pharmaceutical Co Ltd's stock price CN¥3.33 by its total outstanding shares 791927400 (791.93 Million). See capital reinvestment ratio of Guizhou Yibai Pharmaceutical Co Ltd to understand how much of operating cash flow is reinvested back into capital assets.
Guizhou Yibai Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Guizhou Yibai Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.16 Billion to $385.89 Million (-13.74% CAGR).
Guizhou Yibai Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guizhou Yibai Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.25x
Guizhou Yibai Pharmaceutical Co Ltd's market cap is 0.25 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.70 Billion | $3.69 Billion | $384.86 Million | 0.46x | 4.42x |
| 2017 | $1.05 Billion | $3.81 Billion | $387.53 Million | 0.28x | 2.70x |
| 2018 | $569.08 Million | $3.88 Billion | -$725.50 Million | 0.15x | N/A |
| 2019 | $513.41 Million | $3.36 Billion | $141.90 Million | 0.15x | 3.62x |
| 2020 | $591.63 Million | $3.41 Billion | $228.76 Million | 0.17x | 2.59x |
| 2021 | $942.14 Million | $3.35 Billion | $243.77 Million | 0.28x | 3.86x |
| 2022 | $640.84 Million | $2.74 Billion | -$426.39 Million | 0.23x | N/A |
| 2023 | $659.38 Million | $2.82 Billion | $103.40 Million | 0.23x | 6.38x |
| 2024 | $412.55 Million | $2.17 Billion | -$317.22 Million | 0.19x | N/A |
| 2025 | $461.22 Million | $1.86 Billion | -$329.56 Million | 0.25x | N/A |
Competitor Companies of 600594 by Market Capitalization
Companies near Guizhou Yibai Pharmaceutical Co Ltd in the global market cap rankings as of July 22, 2026.
Key companies related to Guizhou Yibai Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #505 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #515 globally with a market cap of $51.87 Billion USD ( CN¥354.48 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #548 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #617 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #505 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #515 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $51.87 Billion | CN¥55.57 |
| #548 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.46 |
| #617 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.80 |
Guizhou Yibai Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Guizhou Yibai Pharmaceutical Co Ltd's market cap moved from $2.16 Billion to $ 385.89 Million, with a yearly change of -13.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥385.89 Million | -16.33% |
| 2025 | CN¥461.22 Million | +11.80% |
| 2024 | CN¥412.55 Million | -37.43% |
| 2023 | CN¥659.38 Million | +2.89% |
| 2022 | CN¥640.84 Million | -31.98% |
| 2021 | CN¥942.14 Million | +59.24% |
| 2020 | CN¥591.63 Million | +15.24% |
| 2019 | CN¥513.41 Million | -9.78% |
| 2018 | CN¥569.08 Million | -45.69% |
| 2017 | CN¥1.05 Billion | -38.35% |
| 2016 | CN¥1.70 Billion | -21.37% |
| 2015 | CN¥2.16 Billion | -- |
End of Day Market Cap According to Different Sources
On Jul 21st, 2026 the market cap of Guizhou Yibai Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $385.89 Million USD |
| MoneyControl | $385.89 Million USD |
| MarketWatch | $385.89 Million USD |
| marketcap.company | $385.89 Million USD |
| Reuters | $385.89 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system… Read more